Nanologica AB (NICA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nanologica AB (NICA) has a cash flow conversion efficiency ratio of -0.064x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.22 Million ≈ $-669.05K USD) by net assets (Skr97.50 Million ≈ $10.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Nanologica AB balance sheet quality to measure how much of total assets are equity-financed.
Nanologica AB - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Nanologica AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Nanologica AB to evaluate the quality of earnings relative to operating cash generation.
Nanologica AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanologica AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KOAS Co. Ltd
KO:071950
|
0.001x |
|
Floyd Public Company Limited
BK:FLOYD
|
0.048x |
|
Barnwell Industries Inc
NYSE MKT:BRN
|
-0.216x |
|
BPM Minerals Ltd
AU:BPM
|
-0.165x |
|
CANADIAN NORTH RESOURCES
F:EO0
|
0.006x |
|
G3 Global Bhd
KLSE:7184
|
-0.010x |
|
Southern Hemisphere Mining Ltd
AU:SUH
|
-1.457x |
|
JPMorgan Japanese Investment Trust
LSE:JFJ
|
0.003x |
Annual Cash Flow Conversion Efficiency for Nanologica AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of Nanologica AB from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Nanologica AB market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr22.64 Million ≈ $2.44 Million |
Skr-39.88 Million ≈ $-4.29 Million |
-1.761x | -61.68% |
| 2024-12-31 | Skr74.11 Million ≈ $7.98 Million |
Skr-80.73 Million ≈ $-8.69 Million |
-1.089x | -105.77% |
| 2023-12-31 | Skr-1.90 Million ≈ $-204.26K |
Skr-35.85 Million ≈ $-3.86 Million |
18.887x | +3155.69% |
| 2022-12-31 | Skr73.16 Million ≈ $7.87 Million |
Skr-45.22 Million ≈ $-4.87 Million |
-0.618x | +31.41% |
| 2021-12-31 | Skr51.60 Million ≈ $5.55 Million |
Skr-46.49 Million ≈ $-5.00 Million |
-0.901x | -93.29% |
| 2020-12-31 | Skr92.97 Million ≈ $10.00 Million |
Skr-43.34 Million ≈ $-4.66 Million |
-0.466x | +83.33% |
| 2019-12-31 | Skr4.12 Million ≈ $443.48K |
Skr-11.52 Million ≈ $-1.24 Million |
-2.796x | -466.33% |
| 2018-12-31 | Skr23.71 Million ≈ $2.55 Million |
Skr-11.71 Million ≈ $-1.26 Million |
-0.494x | +95.87% |
| 2017-12-31 | Skr1.94 Million ≈ $208.60K |
Skr-23.19 Million ≈ $-2.50 Million |
-11.965x | -1036.92% |
| 2016-12-31 | Skr22.03 Million ≈ $2.37 Million |
Skr-23.19 Million ≈ $-2.50 Million |
-1.052x | -82.15% |
| 2015-12-31 | Skr24.14 Million ≈ $2.60 Million |
Skr-13.95 Million ≈ $-1.50 Million |
-0.578x | -- |
About Nanologica AB
Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange prod… Read more